These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37243261)

  • 1. Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression.
    Franco EJ; Drusano GL; Hanrahan KC; Warfield KL; Brown AN
    Viruses; 2023 May; 15(5):. PubMed ID: 37243261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UV-4B potently inhibits replication of multiple SARS-CoV-2 strains in clinically relevant human cell lines.
    Franco EJ; Warfield KL; Brown AN
    Front Biosci (Landmark Ed); 2022 Jan; 27(1):3. PubMed ID: 35090308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants.
    Chang CW; Parsi KM; Somasundaran M; Vanderleeden E; Liu P; Cruz J; Cousineau A; Finberg RW; Kurt-Jones EA
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites.
    Miller SR; McGrath ME; Zorn KM; Ekins S; Wright SH; Cherrington NJ
    Mol Pharmacol; 2021 Dec; 100(6):548-557. PubMed ID: 34503974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
    Siniavin AE; Gushchin VA; Shastina NS; Darnotuk ES; Luyksaar SI; Russu LI; Inshakova AM; Shidlovskaya EV; Vasina DV; Kuznetsova NA; Savina DM; Zorkov ID; Dolzhikova IV; Sheremet AB; Logunov DY; Zigangirova NA; Gintsburg AL
    Antiviral Res; 2024 May; 225():105871. PubMed ID: 38555022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Evaluation of UV-4B and Interferon-Alpha Combination Regimens against Dengue Virus.
    Franco EJ; Pires de Mello CP; Brown AN
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33925551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2.
    Pandey K; Acharya A; Pal D; Jain P; Singh K; Durden DL; Kutateladze TG; Deshpande AJ; Byrareddy SN
    Antiviral Res; 2024 Jul; 227():105904. PubMed ID: 38729306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and anti-SARS-CoV-2 evaluation of lipid prodrugs of β-D-N
    Wen ZH; Wang MM; Li LY; Herdewijn P; Snoeck R; Andrei G; Liu ZP; Liu C
    Bioorg Chem; 2023 Jun; 135():106527. PubMed ID: 37031504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Trimeric Artesunate Analog TF27, a Broadly Acting Anti-Infective Model Drug, Exerts Pronounced Anti-SARS-CoV-2 Activity Spanning Variants and Host Cell Types.
    Hahn F; Wangen C; Häge S; Herrmann L; Herrmann A; Tsogoeva SB; Marschall M
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
    Ohashi H; Hishiki T; Akazawa D; Kim KS; Woo J; Shionoya K; Tsuchimoto K; Iwanami S; Moriyama S; Kinoshita H; Yamada S; Kuroda Y; Yamamoto T; Kishida N; Watanabe S; Hasegawa H; Ebihara H; Suzuki T; Maeda K; Fukushi S; Takahashi Y; Iwami S; Watashi K
    Antiviral Res; 2022 Sep; 205():105372. PubMed ID: 35798223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.
    Singla S; Goyal S
    Bull Natl Res Cent; 2022; 46(1):62. PubMed ID: 35287311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo.
    Li Y; Liu M; Yan Y; Wang Z; Dai Q; Yang X; Guo X; Li W; Chen X; Cao R; Zhong W
    Viruses; 2022 May; 14(6):. PubMed ID: 35746614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern.
    Vanhulle E; D'huys T; Provinciael B; Stroobants J; Camps A; Noppen S; Schols D; Van Damme EJM; Maes P; Stevaert A; Vermeire K
    Front Cell Infect Microbiol; 2022; 12():989534. PubMed ID: 36111239
    [No Abstract]   [Full Text] [Related]  

  • 17. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
    Strizki JM; Gaspar JM; Howe JA; Hutchins B; Mohri H; Nair MS; Kinek KC; McKenna P; Goh SL; Murgolo N
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0095323. PubMed ID: 38047645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
    Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
    J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4'-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness.
    Lieber CM; Plemper RK
    DNA Cell Biol; 2022 Aug; 41(8):699-704. PubMed ID: 35788144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters.
    Abdelnabi R; Maes P; de Jonghe S; Weynand B; Neyts J
    Front Pharmacol; 2022; 13():1072202. PubMed ID: 36605401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.